SAN DIEGO, CA--(Marketwired - Nov 24, 2014) - NuVasive, Inc. (
- The 26 th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel in New York, New York, on Tuesday, December 2, 2014, at 10:00 a.m. ET
- The Leerink Swann Devices & DNA Bus Tour at NuVasive's headquarters on Wednesday, December 10, 2014, at 2:00 p.m. PT
- The Stifel MedTech Madness Bus Tour at NuVasive's headquarters on Thursday, December 18, 2014 at 4:00 p.m. PT
A live webcast of each of the presentations will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com . After the live webcast, a replay of each presentation will remain available on the website for 30 days.
About NuVasive
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally-integrated solutions for the spine. The Company is the third largest player in the $8.7 billion global spine market. NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS was designed to provide safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
NuVasive cautions you that statements included in this press release or by management when participating in the above-described events that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, expansion of our network of sales representatives, and the other risks and uncertainties described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov . NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Investor/Media Contact: Stacy Roughan NuVasive, Inc. 1-858-909-1812 Email Contact
